News | May 27, 2021
Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
India sales grew 23.5% YoY with consolidation of Wockhardt products
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Subscribe To Our Newsletter & Stay Updated
